Cited by 324SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesRespiratory viral infections research

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Recent endemic coronavirus infection is associated with less severe COVID-19

Open access

Sagar, Manish, Reifler, Katherine, Rossi, Michael, Miller, Nancy S., Sinha, Pranay, White, Laura F., Mizgerd, Joseph P.·2021·Journal of Clinical Investigation

DOI 10.1172/jci143380PMC PMC7773342

Open this paper in CoChat — free account Open PDF

Abstract

Four different endemic coronaviruses (eCoVs) are etiologic agents for the seasonal common cold, and these eCoVs share extensive sequence homology with human SARS coronavirus 2 (SARS-CoV-2). Here, we show that individuals with, as compared with those without, a recent documented infection with eCoV were tested at greater frequency for respiratory infections but had a similar rate of SARS-CoV-2 acquisition. Importantly, the patients with a previously detected eCoV had less-severe coronavirus disease 2019 (COVID-19) illness. Our observations suggest that preexisting immune responses against endemic human coronaviruses can mitigate disease manifestations from SARS-CoV-2 infection.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1172/jci143380

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area
Richardson, S., Hirsch, J. S., Narasimhan, M., Crawford, J. M., McGinn, T., Davidson, K. W., and the Northwell COVID-19 Research Consortium, Barnaby, D. P., Becker, L. B., Chelico, J. D., et al. (2020) · JAMA · doi:10.1001/jama.2020.6775 · Cited by 9,254
Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China
Wu, C., Chen, X., Cai, Y., Xia, J., Zhou, X., Xu, S., Huang, H., Zhang, L., Zhou, X., Du, C., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.0994 · Cited by 8,249
Clinical and immunological features of severe and moderate coronavirus disease 2019
Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., Wang, T., Zhang, X., Chen, H., Yu, H., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137244 · Cited by 4,750
Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19
Blanco-Melo, D., Nilsson-Payant, B. E., Liu, W.-C., Uhl, S., Hoagland, D., Møller, R., Jordan, T. X., Oishi, K., Panis, M., Sachs, D., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.026 · Cited by 4,222
Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals
Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
Hadjadj, J., Yatim, N., Barnabei, L., Corneau, A., Boussier, J., Smith, N., Péré, H., Charbit, B., Bondet, V., Chenevier-Gobeaux, C., et al. (2020) · Science · doi:10.1126/science.abc6027 · Cited by 2,984
Prevalence of Asymptomatic SARS-CoV-2 Infection
Oran, D. P., & Topol, E. J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-3012 · Cited by 2,348
Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 - COVID-NET, 14 states, march 1-30, 2020
Garg, S., Kim, L., Whitaker, M., O’Halloran, A., Cummings, C., Holstein, R., Prill, M., Chai, S. J., Kirley, P. D., Alden, N. B., et al. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6915e3 · Cited by 2,335
Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults
Jain, S., Self, W. H., Wunderink, R. G., Fakhran, S., Balk, R., Bramley, A. M., Reed, C., Grijalva, C. G., Anderson, E. J., Courtney, D. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500245 · Cited by 2,323
SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls
Le Bert, N., Tan, A. T., Kunasegaran, K., Tham, C. Y. L., Hafezi, M., Chia, A., Chng, M. H. Y., Lin, M., Tan, N., Linster, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2550-z · Cited by 1,887

Show all 20 references

Research works printed but not linked: 1

10.1016/j.medj.2020.05 · DOI

Sorted by citations

Adaptive immunity to SARS-CoV-2 and COVID-19
Sette, A., & Crotty, S. (2021) · Cell · doi:10.1016/j.cell.2021.01.007 · Cited by 1,860
The T cell immune response against SARS-CoV-2
Moss, P. A. H. (2022) · Nature Immunology · doi:10.1038/s41590-021-01122-w · Cited by 1,243
Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2
Swadling, L., Diniz, M. O., Schmidt, N. M., Amin, O. E., Chandran, A., Shaw, E., Pade, C., Gibbons, J. M., Bert, N. L., Tan, A. T., et al. (2021) · Nature · doi:10.1038/s41586-021-04186-8 · Cited by 398
Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection
Anderson, E. M., Goodwin, E. C., Verma, A., Arevalo, C. P., Bolton, M. J., Weirick, M. E., Gouma, S., McAllister, C. M., Christensen, S. R., Weaver, J., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.010 · Cited by 381
Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells
(2021) · doi:10.1126/science.abj9853 · Cited by 327
SARS-CoV-2 human T cell epitopes: Adaptive immune response against COVID-19
Grifoni, A., Sidney, J., Vita, R., Peters, B., Crotty, S., Weiskopf, D., & Sette, A. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.05.010 · Cited by 314
Correlates of protection against SARS ‐ CoV ‐2 infection and COVID‐19 disease
Goldblatt, D., Alter, G., Crotty, S., & Plotkin, S. A. (2022) · Immunological Reviews · doi:10.1111/imr.13091 · Cited by 301
Cross-reactive CD4 + T cells enhance SARS-CoV-2 immune responses upon infection and vaccination
Loyal, L., Braun, J., Henze, L., Kruse, B., Dingeldey, M., Reimer, U., Kern, F., Schwarz, T., Mangold, M., Unger, C., et al. (2021) · Science · doi:10.1126/science.abh1823 · Cited by 293
Immunological memory to SARS‐CoV ‐2 infection and COVID ‐19 vaccines
Sette, A., & Crotty, S. (2022) · Immunological Reviews · doi:10.1111/imr.13089 · Cited by 270
Humoral Responses and Serological Assays in SARS-CoV-2 Infections
Galipeau, Y., Greig, M., Liu, C., Driedger, M., & Langlois, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.610688 · Cited by 247
Viral persistence, reactivation, and mechanisms of long COVID
Chen, B. K., Jülg, B. D., Mohandas, S., Bradfute, S. B., & RECOVER Mechanistic Pathways Task Force (2023) · eLife · doi:10.7554/elife.86015 · Cited by 211
T Cell Responses to SARS-CoV-2
Sette, A., Sidney, J., & Crotty, S. (2023) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101721-061120 · Cited by 191
The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses
Murray, S. M., Ansari, M. A., Frater, J., Klenerman, P., Dunachie, S. J., Barnes, E. J., & Ogbe, A. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-022-00809-x · Cited by 173
Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses
Ortega, N., Ribes, M., Vidal, M., Rubio, R., Aguilar, R., Williams, S. V., Barrios, D., Alonso, S., Hernández-Luis, P., Mitchell, R. A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24979-9 · Cited by 174
The Conundrum of Low COVID-19 Mortality Burden in sub-Saharan Africa: Myth or Reality?
Adams, J. A., MacKenzie, M. J., Amegah, A. K., Ezeh, A., Gadanya, M. A., Omigbodun, A. O., Sarki, A. M., Thistle, P., Ziraba, A. K., Stranges, S., et al. (2021) · Global Health Science and Practice · doi:10.9745/ghsp-d-21-00172 · Cited by 150
Antibody and B cell responses to SARS-CoV-2 infection and vaccination
Röltgen, K., & Boyd, S. D. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.06.009 · Cited by 143
SARS-CoV-2 Omicron Variant: Epidemiological Features, Biological Characteristics, and Clinical Significance
Guo, Y., Han, J., Zhang, Y., He, J., Yu, W., Zhang, X., Wu, J., Zhang, S., Kong, Y., Guo, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.877101 · Cited by 118
Distinct Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Convalescent Individuals
Butler, S. E., Crowley, A. R., Natarajan, H., Xu, S., Weiner, J. A., Bobak, C. A., Mattox, D. E., Lee, J., Wieland‐Alter, W., Connor, R. I., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.618685 · Cited by 120
SARS-CoV-2 infections in children: Understanding diverse outcomes
Brodin, P. (2022) · Immunity · doi:10.1016/j.immuni.2022.01.014 · Cited by 118
SARS-CoV-2-specific T cells in the changing landscape of the COVID-19 pandemic
Bertoletti, A., Bert, N. L., & Tan, A. T. (2022) · Immunity · doi:10.1016/j.immuni.2022.08.008 · Cited by 118
Risk Factors of Severe COVID-19: A Review of Host, Viral and Environmental Factors
Zsichla, L., & Müller, V. (2023) · Viruses · doi:10.3390/v15010175 · Cited by 121
Immunogenicity and crossreactivity of antibodies to the nucleocapsid protein of SARS-CoV-2: utility and limitations in seroprevalence and immunity studies
Dobaño, C., Santano, R., Jiménez, A., Vidal, M., Chi, J., Melero, N. R., Popovic, M., López-Aladid, R., Fernández‐Barat, L., Tortajada, M., et al. (2021) · Translational research · doi:10.1016/j.trsl.2021.02.006 · Cited by 110
Lung-resident memory B cells protect against bacterial pneumonia
Barker, K. A., Etesami, N. S., Shenoy, A. T., Arafa, E. I., Ana, C. L. D., Smith, N. M. S., Martin, I. M. C., Goltry, W. N., Barron, A., Browning, J. L., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci141810 · Cited by 106
Self-citation
Cross-reactive antibodies after SARS-CoV-2 infection and vaccination
Grobben, M., van der Straten, K., Brouwer, P. J. M., Brinkkemper, M., Maisonnasse, P., Dereuddre‐Bosquet, N., Appelman, B., Lavell, A. H. A., van Vught, L. A., Burger, J. A., et al. (2021) · eLife · doi:10.7554/elife.70330 · Cited by 103
Pre-existing humoral immunity to human common cold coronaviruses negatively impacts the protective SARS-CoV-2 antibody response
Lin, C.-Y., Wolf, J., Brice, D. C., Sun, Y., Locke, M., Cherry, S., Castellaw, A. H., Wehenkel, M., Crawford, J. C., Zarnitsyna, V. I., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.12.005 · Cited by 103
RETRACTED: SARS-CoV-2 S2–targeted vaccination elicits broadly neutralizing antibodies
Ng, K. W., Faulkner, N., Finsterbusch, K., Wu, M., Harvey, R., Hussain, S., Greco, M., Liu, Y., Kjær, S., Swanton, C., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn3715 · Cited by 100
Retracted
Cross-Reactive Antibody Against Human Coronavirus OC43 Spike Protein Correlates with Disease Severity in COVID-19 Patients: A Retrospective Study
Guo, L., Wang, Y., Kang, L., Hu, Y., Wang, L., Zhong, J., Chen, H., Ren, L., Gu, X., Wang, G., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1905488 · Cited by 93
Identification of resident memory CD8 + T cells with functional specificity for SARS-CoV-2 in unexposed oropharyngeal lymphoid tissue
Niessl, J., Sekine, T., Lange, J., Kónya, V., Forkel, M., Marić, J., Rao, A., Mazzurana, L., Kokkinou, E., Weigel, W., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abk0894 · Cited by 94
Why Does the Severity of COVID-19 Differ With Age?
Zimmermann, P., & Curtis, N. C. (2021) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000003413 · Cited by 89
Epidemiology, Clinical Significance, and Diagnosis of Respiratory Viruses and Their Co-Infections in the Post-COVID Era
Contes, K. M., & Liu, B. (2025) · Pathogens · doi:10.3390/pathogens14030262 · Cited by 86
In search of a pan-coronavirus vaccine: next-generation vaccine design and immune mechanisms
Cankat, S., Demael, M. U., & Swadling, L. (2023) · Cellular & Molecular Immunology · doi:10.1038/s41423-023-01116-8 · Cited by 84
Antibody responses to endemic coronaviruses modulate COVID-19 convalescent plasma functionality
Morgenlander, W. R., Henson, S. N., Monaco, D. R., Chen, A., Littlefield, K. E., Bloch, E. M., Fujimura, E., Ruczinski, I., Crowley, A. R., Natarajan, H., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci146927 · Cited by 86
Functional characterization of CD4+ T cell receptors crossreactive for SARS-CoV-2 and endemic coronaviruses
Dykema, A. G., Zhang, B., Woldemeskel, B. A., Garliss, C. C., Cheung, L. S., Choudhury, D. M., Zhang, J., Aparicio, L., Bom, S., Rashid, R., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci146922 · Cited by 85
Robust and durable serological response following pediatric SARS-CoV-2 infection
Renk, H., Dulovic, A., Seidel, A., Becker, M., Fabricius, D., Zernickel, M., Junker, D., Groß, R. M., Müller, J. A., Hilger, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27595-9 · Cited by 81
Cross-protective immunity following coronavirus vaccination and coronavirus infection
Dangi, T., Palacio, N. M., Sanchez, S., Park, M., Class, J., Visvabharathy, L., Ciucci, T., Koralnik, I. J., Richner, J. M., & Penaloza-MacMaster, P. (2021) · Journal of Clinical Investigation · doi:10.1172/jci151969 · Cited by 79
COVID-19—Lessons Learned and Questions Remaining
Fang, F. C., Benson, C. A., del Río, C., Edwards, K. M., Fowler, V. G., Fredricks, D. N., Limaye, A. P., Murray, B. E., Naggie, S., Pappas, P. G., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1654 · Cited by 78
Evolution of SARS-CoV-2: Review of Mutations, Role of the Host Immune System
Banoun, H. (2021) · The Nephron journals/Nephron journals · doi:10.1159/000515417 · Cited by 77
Natural killer cell‐mediated ADCC in SARS‐CoV‐2‐infected individuals and vaccine recipients
Hagemann, K., Riecken, K., Jung, J. M., Hildebrandt, H., Menzel, S., Bunders, M. J., Fehse, B., Koch‐Nolte, F., Heinrich, F., Peine, S., et al. (2022) · European Journal of Immunology · doi:10.1002/eji.202149470 · Cited by 76
T cell immunity to SARS-CoV-2
Niessl, J., Sekine, T., & Buggert, M. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101505 · Cited by 77
A comparative characterization of SARS-CoV-2-specific T cells induced by mRNA or inactive virus COVID-19 vaccines
Lim, J. M. E., Hang, S. K., Hariharaputran, S., Chia, A., Tan, N., Lee, E. S., Chng, E., Lim, P. L., Young, B. E., Lye, D. C., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100793 · Cited by 73
Differential T-Cell Reactivity to Endemic Coronaviruses and SARS-CoV-2 in Community and Health Care Workers
Antunes, R. D. S., Pallikkuth, S., Williams, E., Yu, E. D., Mateus, J., Quiambao, L. G., Wang, E. W., Rawlings, S. A., Stadlbauer, D., Jiang, K., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab176 · Cited by 70
COVID-19 Mechanisms in the Human Body—What We Know So Far
Kumar, A., Narayan, R. K., Prasoon, P., Kumari, C., Kaur, G., Kumar, S., Kulandhasamy, M., Sesham, K., Pareek, V., Faiq, M. A., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.693938 · Cited by 76
The T-cell response to SARS-CoV-2: kinetic and quantitative aspects and the case for their protective role
Bertoletti, A., Tan, A. T., & Bert, N. L. (2021) · Oxford Open Immunology · doi:10.1093/oxfimm/iqab006 · Cited by 69
Immune imprinting and next-generation coronavirus vaccines
Huang, C. Q., Vishwanath, S., Carnell, G., Chan, A. C. Y., & Heeney, J. L. (2023) · Nature Microbiology · doi:10.1038/s41564-023-01505-9 · Cited by 68
Defending against SARS-CoV-2: The T cell perspective
Almendro-Vázquez, P., Laguna‐Goya, R., & Paz‐Artal, E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1107803 · Cited by 67
Instructing durable humoral immunity for COVID-19 and other vaccinable diseases
Bhattacharya, D. (2022) · Immunity · doi:10.1016/j.immuni.2022.05.004 · Cited by 64
T cell immune memory after covid-19 and vaccination
Wang, L., Nicols, A. R., Turtle, L. C. W., Richter, A. G., Duncan, C. J. A., Dunachie, S. J., Klenerman, P., & Payne, R. (2023) · BMJ Medicine · doi:10.1136/bmjmed-2022-000468 · Cited by 66
A majority of uninfected adults show preexisting antibody reactivity against SARS-CoV-2
Majdoubi, A., Michalski, C., O’Connell, S. E., Dada, S., Narpala, S., Gelinas, J. P., Mehta, D., Cheung, C., Winkler, D. F. H., Basappa, M., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.146316 · Cited by 57
Detection of Serum Cross-Reactive Antibodies and Memory Response to SARS-CoV-2 in Prepandemic and Post–COVID-19 Convalescent Samples
Shrwani, K. J., Sharma, R. S., Krishnan, M., Jones, T., Neto, M. M., Cantoni, D. M., Temperton, N. J., Dobson, S. L., Subramaniam, K. S., McNamara, P. S., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab333 · Cited by 58
Less severe course of COVID-19 is associated with elevated levels of antibodies against seasonal human coronaviruses OC43 and HKU1 (HCoV OC43, HCoV HKU1)
Dugas, M., Grote-Westrick, T., Vollenberg, R., Lorentzen, E. U., Brix, T. J., Schmidt, H., Tepasse, P., & Kühn, J. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.02.085 · Cited by 57
Evidence for increased SARS-CoV-2 susceptibility and COVID-19 severity related to pre-existing immunity to seasonal coronaviruses
Wratil, P. R., Schmacke, N. A., Karakoc, B., Dulovic, A., Junker, D., Becker, M., Rothbauer, U., Osterman, A., Späth, P. M., Ruhle, A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110169 · Cited by 57
Previous immunity shapes immune responses to SARS-CoV-2 booster vaccination and Omicron breakthrough infection risk
Pérez‐Alós, L., Hansen, C. B., Armenteros, J. J. A., Madsen, J. R., Heftdal, L. D., Hasselbalch, R. B., Pries‐Heje, M. M., Bayarri‐Olmos, R., Jarlhelt, I., Hamm, S. R., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41342-2 · Cited by 53
Pre-existing T cell-mediated cross-reactivity to SARS-CoV-2 cannot solely be explained by prior exposure to endemic human coronaviruses
Tan, C. C. S., Owen, C. J., Tham, C. Y. L., Bertoletti, A., van Dorp, L., & Balloux, F. (2021) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2021.105075 · Cited by 54
Relative Ratios of Human Seasonal Coronavirus Antibodies Predict the Efficiency of Cross-Neutralization of SARS-CoV-2 Spike Binding to ACE2
Galipeau, Y., Siragam, V., Laroche, G., Marion, E., Greig, M., McGuinty, M., Booth, R. A., Durocher, Y., Čuperlović‐Culf, M., Bennett, S. A. L., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103700 · Cited by 56
Boosting of cross-reactive antibodies to endemic coronaviruses by SARS-CoV-2 infection but not vaccination with stabilized spike
Crowley, A. R., Natarajan, H., Hederman, A. P., Bobak, C. A., Weiner, J. A., Wieland-Alter, W., Lee, J., Bloch, E. M., Tobian, A. A. R., Redd, A. D., et al. (2022) · eLife · doi:10.7554/elife.75228 · Cited by 51
Pre-existing T-cell immunity to SARS-CoV-2 in unexposed healthy controls in Ecuador, as detected with a COVID-19 Interferon-Gamma Release Assay
Echeverría, G. A., Guevara, A. G., Coloma, J., Ruiz, A. M., Vasquez, M. M., Tejera, E., & de Waard, J. H. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.02.034 · Cited by 49
The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection
Moga, E., Lynton‐Pons, E., & Domingo, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.904686 · Cited by 48
Immunity to SARS-CoV-2: Lessons Learned
FERGIE, J. E., & Srivastava, A. K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.654165 · Cited by 46
Neutralizing antibody responses following natural SARS-CoV-2 infection: Dynamics and correlation with commercial serologic tests.
Montesinos, I., Dahma, H., Wolff, F., Dauby, N., Delaunoy, S., Wuyts, M., Detemmerman, C., Duterme, C., Vandenberg, O., Martin, C., et al. (2021) · Journal of Clinical Virology · doi:10.1016/j.jcv.2021.104988 · Cited by 44
Immunomodulation as Treatment for Severe Coronavirus Disease 2019: A Systematic Review of Current Modalities and Future Directions
Meyerowitz, E. A., Sen, P., Schoenfeld, S. R., Neilan, T. G., Frigault, M. J., Stone, J. H., Kim, A. Y., & Mansour, M. K. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1759 · Cited by 47
Lack of antibodies against seasonal coronavirus OC43 nucleocapsid protein identifies patients at risk of critical COVID-19
Dugas, M., Grote-Westrick, T., Merle, U., Fontenay, M., Kremer, A. E., Hanses, F., Vollenberg, R., Lorentzen, E. U., Tiwari‐Heckler, S., Duchemin, J., et al. (2021) · Journal of Clinical Virology · doi:10.1016/j.jcv.2021.104847 · Cited by 45
COVID ‐19 and plasma cells: Is there long‐lived protection?*
Nguyen, D. C., Lamothe, P. A., Woodruff, M. C., Saini, A. S., Faliti, C. E., Sanz, I., & Lee, F. E.-H. (2022) · Immunological Reviews · doi:10.1111/imr.13115 · Cited by 48
Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation
Meyers, L. M., Gutiérrez, A. H., Boyle, C., Terry, F. E., McGonnigal, B., Salazar, A. Μ., Princiotta, M. F., Martin, W. D., Groot, A. S. D., & Moise, L. (2021) · npj Vaccines · doi:10.1038/s41541-021-00331-6 · Cited by 44
Mouse models susceptible to HCoV-229E and HCoV-NL63 and cross protection from challenge with SARS-CoV-2
Liu, D., Chen, C., Chen, D., Zhu, A., Li, F., Zhuang, Z., Mok, C. K. P., Dai, J., Li, X., Jin, Y., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2202820120 · Cited by 43
Nanomedicine: A Diagnostic and Therapeutic Approach to COVID-19
Sharma, A., Kontodimas, K., & Bosmann, M. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.648005 · Cited by 39
The past, current and future epidemiological dynamic of SARS-CoV-2
Balloux, F., Tan, C. C. S., Swadling, L., Richard, D., Jenner, C., Maini, M. K., & van Dorp, L. (2022) · Oxford Open Immunology · doi:10.1093/oxfimm/iqac003 · Cited by 41
Cross-Reactive Antibodies to SARS-CoV-2 and MERS-CoV in Pre-COVID-19 Blood Samples from Sierra Leoneans
Borrega, R., Nelson, D. K. S., Koval, A. P., Bond, N. G., Heinrich, M. L., Rowland, M. M., Lathigra, R. B., Bush, D. J., Aimukanova, I., Phinney, W. N., et al. (2021) · Viruses · doi:10.3390/v13112325 · Cited by 37
Pernio (Chilblains), SARS-CoV-2, and COVID Toes Unified Through Cutaneous and Systemic Mechanisms
Cappel, M. A., Cappel, J. A., & Wetter, D. A. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2021.01.009 · Cited by 36
The interactions of SARS-CoV-2 with cocirculating pathogens: Epidemiological implications and current knowledge gaps
Wong, A., Guevara, L. A. B., Goult, E., Briga, M., Krämer, S., Kovacevic, A., Opatowski, L., & de Cellès, M. D. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011167 · Cited by 37
Mechanistic Insights Into the Immune Pathophysiology of COVID-19; An In-Depth Review
Shafqat, A., Shafqat, S., Alsalameh, S., Kashir, J., AlKattan, K. M., & Yaqinuddin, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.835104 · Cited by 37
Targets and cross-reactivity of human T cell recognition of common cold coronaviruses
Tarke, A., Zhang, Y., Methot, N., Narowski, T. M., Phillips, E. J., Mallal, S. A., Frazier, A., Filaci, G., Weiskopf, D., Dan, J. M., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101088 · Cited by 39
Divergent trajectories of antiviral memory after SARS-CoV-2 infection
Tomić, A., Skelly, D., Ogbe, A., O’Connor, D., Pace, M. J., Adland, E., Alexander, F., Ali, M., Allott, K., Ansari, M. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28898-1 · Cited by 35
Cross-reactive and mono-reactive SARS-CoV-2 CD4+ T cells in prepandemic and COVID-19 convalescent individuals
Johansson, A. M., Malhotra, U., Kim, Y. G., Gomez, R., Krist, M. P., Wald, A., Koelle, D. M., & Kwok, W. W. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1010203 · Cited by 35
Broadly recognized, cross-reactive SARS-CoV-2 CD4 T cell epitopes are highly conserved across human coronaviruses and presented by common HLA alleles
Becerra‐Artiles, A., Calvo‐Calle, J. M., Co, M. D. T., Nanaware, P. P., Cruz, J., Weaver, G. C., Lu, L., Forconi, C. S., Finberg, R. W., Moormann, A. M., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110952 · Cited by 36
SARS-CoV-2 infections elicit higher levels of original antigenic sin antibodies compared with SARS-CoV-2 mRNA vaccinations
Anderson, E. M., Li, S. H., Awofolaju, M., Eilola, T., Goodwin, E. C., Bolton, M. J., Gouma, S., Manzoni, T. B., Hicks, P. D., Goel, R. R., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111496 · Cited by 37
Role of antiviral CD8+ T cell immunity to SARS-CoV-2 infection and vaccination
Karl, V., Hofmann, M., & Thimme, R. (2025) · Journal of Virology · doi:10.1128/jvi.01350-24 · Cited by 37
Immunological memory to common cold coronaviruses assessed longitudinally over a three-year period pre-COVID19 pandemic
Yu, E. D., Narowski, T. M., Wang, E. W., Garrigan, E., Mateus, J., Frazier, A., Weiskopf, D., Grifoni, A., Premkumar, L., Antunes, R. D. S., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.07.012 · Cited by 32
Innate and adaptive immunity to SARS-CoV-2 and predisposing factors
Shen, J., Fan, J., Zhao, Y., Jiang, D., Niu, Z., Zhang, Z., & Cao, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1159326 · Cited by 38
Health care worker seromonitoring reveals complex relationships between common coronavirus antibodies and COVID-19 symptom duration
Gouma, S., Weirick, M. E., Bolton, M. J., Arevalo, C. P., Goodwin, E. C., Anderson, E. M., McAllister, C. M., Christensen, S. R., Dunbar, D., Fiore, D., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.150449 · Cited by 30
Persistence of Functional Memory B Cells Recognizing SARS-CoV-2 Variants Despite Loss of Specific IgG
Winklmeier, S., Eisenhut, K., Taskin, D., Rübsamen, H., Gerhards, R., Schneider, C., Wratil, P. R., Stern, M., Eichhorn, P., Keppler, O. T., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103659 · Cited by 31
Tracking the clonal dynamics of SARS-CoV-2-specific T cells in children and adults with mild/asymptomatic COVID-19
Khoo, W. H., Jackson, K., Phetsouphanh, C., Zaunders, J., Alquicira-Hernández, J., Yazar, S., Ruiz‐Diaz, S., Singh, M., Dhenni, R., Kyaw, W., et al. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.109209 · Cited by 31
The Integrated Pulmonary Immune Response to Pneumonia
Traber, K. E., & Mizgerd, J. P. (2025) · Annual Review of Immunology · doi:10.1146/annurev-immunol-082323-031642 · Cited by 33
Self-citation
Cross-Reactive Immune Responses toward the Common Cold Human Coronaviruses and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Mini-Review and a Murine Study
Sealy, R. E., & Hurwitz, J. L. (2021) · Microorganisms · doi:10.3390/microorganisms9081643 · Cited by 30
Global Epidemiology and Seasonality of Human Seasonal Coronaviruses: A Systematic Review
Wilson, R., Kovacs, D., Crosby, M., & Ho, A. Y. W. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae418 · Cited by 31
CD4+ T cells from COVID-19 mRNA vaccine recipients recognize a conserved epitope present in diverse coronaviruses
Woldemeskel, B. A., Dykema, A. G., Garliss, C. C., Cherfils, S., Smith, K. N., & Blankson, J. N. (2022) · Journal of Clinical Investigation · doi:10.1172/jci156083 · Cited by 29
Human coronavirus OC43-elicited CD4+ T cells protect against SARS-CoV-2 in HLA transgenic mice
Alves, R. P. D. S., Timis, J., Miller, R., Valentine, K. M., Pinto, P. B. A., Gonzalez, A., Regla-Nava, J. Á., Maule, E., Nguyen, M. N., Shafee, N., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45043-2 · Cited by 29
HCoV-NL63 and SARS-CoV-2 Share Recognized Epitopes by the Humoral Response in Sera of People Collected Pre- and during CoV-2 Pandemic
Simula, E. R., Manca, M. A., Jasemi, S., Uzzau, S., Rubino, S., Manchia, P., Bitti, A., Palermo, M., & Sechi, L. A. (2020) · Microorganisms · doi:10.3390/microorganisms8121993 · Cited by 28
Ophthalmological Considerations for COVID-19 Vaccination in Patients with Inflammatory Eye Diseases and Autoimmune Disorders
Chau, C. Y. C., Chow, L. L. W., Sridhar, S., & Shih, K. C. (2021) · Ophthalmology and Therapy · doi:10.1007/s40123-021-00338-1 · Cited by 27
Development and Application of Human Coronavirus Protein Microarray for Specificity Analysis
Du, P.-X., Chou, Y.-Y., Santos, H. M., Keskin, B. B., Hsieh, M.-H., Ho, T., Wang, J., Lin, Y., & Syu, G. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.1c00614 · Cited by 27
Hallmarks of Severe COVID-19 Pathogenesis: A Pas de Deux Between Viral and Host Factors
Rovito, R., Augello, M., Ben-Haim, A., Bono, V., Monforte, A. D., & Marchetti, G. C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.912336 · Cited by 27
Humoral immunity to an endemic coronavirus is associated with postacute sequelae of COVID-19 in individuals with rheumatic diseases
Herman, J. D., Atyeo, C. G., Zur, Y., Cook, C., Patel, N. J., Vanni, K. M. M., Kowalski, E., Qian, G., Srivatsan, S., Shadick, N. A., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adf6598 · Cited by 27
Antibody and B Cell Responses to SARS-CoV-2 Infection and Vaccination: The End of the Beginning
Röltgen, K., & Boyd, S. D. (2023) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-031521-042754 · Cited by 25
Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination Boosts Neutralizing Activity Against Seasonal Human Coronaviruses
Lawrenz, J., Xie, Q., Zech, F., Weil, T., Seidel, A., Krnavek, D., van der Hoek, L., Münch, J., Müller, J. A., & Kirchhoff, F. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac057 · Cited by 25
Inducing broad-based immunity against viruses with pandemic potential
Sette, A., & Saphire, E. O. (2022) · Immunity · doi:10.1016/j.immuni.2022.04.010 · Cited by 25
Recent Infection With HCoV-OC43 Is Associated With Protection Against Sars-Cov-2 Infection
Lavell, A. H. A., Sikkens, J. J., Edridge, A. W. D., van der Straten, K., Sechan, F., Oomen, M., Buis, D. T. P., Schinkel, M., Burger, J. A., Poniman, M., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105105 · Cited by 25
Prevalence and functional profile of SARS-CoV-2 T cells in asymptomatic Kenyan adults
Samandari, T., Ongalo, J., McCarthy, K. D., Biegon, R., Madiega, P. A., Mithika, A., Orinda, J., Mboya, G., Mwaura, P., Anzala, O. A., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci170011 · Cited by 24
Prospective Assessment of SARS-CoV-2 Seroconversion (PASS) study: an observational cohort study of SARS-CoV-2 infection and vaccination in healthcare workers
Jackson-Thompson, B. M., Goguet, E., Laing, E. D., Olsen, C. H., Pollett, S. D., Hollis-Perry, M., Maiolatesi, S. E., Illinik, L., Ramsey, K. F., Reyes, A. E., et al. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-06233-1 · Cited by 23
Isolation of Antibodies Against the Spike Protein of SARS-CoV from Pig Serum for Competitive Immunoassay
Jung, J., Bong, J.-H., Kim, T. H., Sung, J. S., Lee, C., Kang, M., Kim, H. O., Shin, H., & Pyun, J. (2021) · BioChip Journal · doi:10.1007/s13206-021-00033-0 · Cited by 22
The immune response as a double‐edged sword: The lesson learnt during the COVID ‐19 pandemic
Agrati, C., Carsetti, R., Bordoni, V., Sacchi, A., Quintarelli, C., Locatelli, F., Ippolito, G., & Capobianchi, M. R. (2022) · Immunology · doi:10.1111/imm.13564 · Cited by 22
Targets of influenza human T-cell response are mostly conserved in H5N1
Sidney, J., Kim, A.-R., de Vries, R. D., Peters, B., Meade, P. S., Krammer, F., Grifoni, A., & Sette, A. (2024) · mBio · doi:10.1128/mbio.03479-24 · Cited by 23

Authors: Sagar, M., Reifler, K., Rossi, M., Miller, N. S., Sinha, P., White, L. F., & Mizgerd, J. P.
Affiliations: Boston University (US)
Corresponding author: Sagar, Manish
Mizgerd, Joseph P.
ORCID: Sagar, Manish
Reifler, Katherine
Miller, Nancy S.
Sinha, Pranay
White, Laura F.
Mizgerd, Joseph P.
Venue: Journal of Clinical Investigation
Publisher: American Society for Clinical Investigation
Published: 2021-01-04
Volume: 131
Issue: 1
ISSN: 0021-9738 (ISSN-L)
1558-8238
DOI: 10.1172/jci143380
PMC: PMC7773342
OpenAlex: W3090049663
Cited by: 324
References: 20
Citations by year: 2026: 13 · 2025: 28 · 2024: 32 · 2023: 59 · 2022: 77 · 2021: 109
FWCI: 8.19
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Clinical Investigation (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (HL-135756, AI-145661, AI-052074, GM-122876)
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Health Sciences › Medicine › Epidemiology › Respiratory viral infections research
Keywords: endemic coronaviruses, SARS-CoV-2, COVID-19 severity, pre-existing immunity, cross-protection, common cold, immune response
MeSH terms: COVID-19, SARS-CoV-2, Adult, Aged, Antibodies, Viral, Female, Humans, Male, Middle Aged, Severity of Illness Index

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Recent endemic coronavirus infection is associated with less severe COVID-19

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks